To evaluate the pharmacokinetic characteristics of ABRJ after a single oral administration in healthy subjects on an empty stomach or after a high-fat meal, as well as the effect of food on the pharmacokinetics of ABRJ.

Start Date08 Jul 2023

Sponsor / Collaborator

Shenyang Yaoda Pharmaceutical Co. Ltd.

[+1]

CTR20220803

/ CompletedNot Applicable

枸橼酸西地那非口崩片人体生物等效性试验

[Translation] Bioequivalence study of sildenafil citrate orodisintegrating tablets in human subjects

主要目的：比较空腹给药条件下单次口服，福州海王福药制药有限公司生产的枸橼酸西地那非口崩片（50mg/片）与Pfizer Limited持证的Fareva Amboise生产的枸橼酸西地那非口崩片（50mg/片，商品名：万艾可®/Viagra®）在健康人群中吸收程度和速度的差异，评价空腹状态下口服两种制剂的生物等效性。次要目的：评价空腹条件下，福州海王福药制药有限公司生产的枸橼酸西地那非口崩片（50mg/片）的安全性和耐受性。

[Translation]

Primary objective: To compare the differences in absorption extent and rate of a single oral administration of sildenafil citrate orodisintegrating tablets (50 mg/tablet) produced by Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. and sildenafil citrate orodisintegrating tablets (50 mg/tablet, trade name: Viagra®) produced by Fareva Amboise, a licensed company of Pfizer Limited, in healthy people under fasting conditions, and to evaluate the bioequivalence of the two oral preparations under fasting conditions. Secondary objective: To evaluate the safety and tolerability of sildenafil citrate orodisintegrating tablets (50 mg/tablet) produced by Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. under fasting conditions.

Start Date19 Apr 2022

Sponsor / Collaborator

Fuzhou Fuyao Pharmaceutical Co. Ltd.

CTR20211553

/ Active, not recruitingPhase 1

评价肿瘤血管阻断剂 HW130 治疗晚期恶性实体瘤患者的安全性、耐受性、药代动力学特征的剂量递增、开放的Ⅰ期临床试验

[Translation] A dose-escalation, open-label Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of the tumor vascular blocking agent HW130 in the treatment of patients with advanced malignant solid tumors

主要目的：评价 HW130 治疗经标准治疗失败的晚期恶性实体瘤患者的安全性和耐受性，并探索 HW130 的最大耐受剂量（MTD），确定Ⅱ期临床试验推荐剂量（RP2D）。次要目的： 1）评价 HW130 的药代动力学（PK）特征； 2）初步评价 HW130 的抗肿瘤疗效；

[Translation]

Primary objectives: To evaluate the safety and tolerability of HW130 in the treatment of patients with advanced malignant solid tumors who have failed standard treatment, and to explore the maximum tolerated dose (MTD) of HW130 and determine the recommended dose (RP2D) for Phase II clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of HW130; 2) To preliminarily evaluate the anti-tumor efficacy of HW130;

Start Date14 Oct 2021

Sponsor / Collaborator

Shenzhen Neptunus Pharmaceutical Research Institute Co. Ltd.

100 Clinical Results associated with Shenzhen Neptunus Bioengineering Co., Ltd.

0 Patents (Medical) associated with Shenzhen Neptunus Bioengineering Co., Ltd.

Literatures (Medical) associated with Shenzhen Neptunus Bioengineering Co., Ltd.

01 Mar 2024·Diabetes

Discovery of a Novel Benzothiadiazine-Based Selective Aldose Reductase Inhibitor as Potential Therapy for Diabetic Peripheral Neuropathy

Article

Author: Guo, Hui ; Xie, Honglei ; Li, Mingyue ; Feng, Haiyu ; Tang, Yuping ; Fu, Ruijia ; Jin, Ruyi ; Zhou, Sha ; Li, Jing ; Wang, Jin ; Guo, Jianshuang ; Wang, Yuwei ; Tang, Tian ; Liu, Jiping ; Nie, Fayi ; Shi, Yajun ; Feng, Yidong

Aldose reductase 2 (ALR2), an activated enzyme in the polyol pathway by hyperglycemia, has long been recognized as one of the most promising targets for complications of diabetes, especially in diabetic peripheral neuropathy (DPN). However, many of the ALR2 inhibitors have shown serious side effects due to poor selectivity over aldehyde reductase (ALR1). Herein, we describe the discovery of a series of benzothiadiazine acetic acid derivatives as potent and selective inhibitors against ALR2 and evaluation of their anti-DPN activities in vivo. Compound 15c, carrying a carbonyl group at the 3-position of the thiadiazine ring, showed high potent inhibition against ALR2 (IC50 = 33.19 nmol/L) and ∼16,109-fold selectivity for ALR2 over ALR1. Cytotoxicity assays ensured the primary biosafety of 15c. Further pharmacokinetic assay in rats indicated that 15c had a good pharmacokinetic feature (t1/2 = 5.60 h, area under the plasma concentration time curve [AUC(0-t)] = 598.57 ± 216.5 μg/mL * h), which was superior to epalrestat (t1/2 = 2.23 h, AUC[0-t] = 20.43 ± 3.7 μg/mL * h). Finally, in a streptozotocin-induced diabetic rat model, 15c significantly increased the nerve conduction velocities of impaired sensory and motor nerves, achieved potent inhibition of d-sorbitol production in the sciatic nerves, and significantly increased the paw withdrawal mechanical threshold. By combining the above investigations, we propose that 15c might represent a promising lead compound for the discovery of an antidiabetic peripheral neuropathy drug.Article Highlights

01 Nov 2017·Molecular DiversityQ3 · CHEMISTRY

Synthesis, insecticidal activities and structure–activity relationship study of dual chiral sulfilimines

Q3 · CHEMISTRY

Article

Author: Meng, Xiangde ; Zhao, Yu ; Song, Hongjian ; Ma, Yi ; Xie, Yongtao ; Zhou, Sha ; Xiong, Lixia ; Li, Zhengming ; Jin, Ruyi

To investigate the "methyl" impact on bioactivity of sulfiliminyl dicarboxamides, a total of 16 novel N-cyano and N-trifluoroacetyl sulfiliminyl dicarboxamides containing m-heptafluoroisopropylated aromatic amino moiety were studied. Two series of sulfiliminyl substituents were designed, synthesized and evaluated against oriental armyworm (Pseudaletia separata Walker) for their insecticidal activities. Their chemical structures were established by corresponding [Formula: see text] NMR, HRMS and optical polarimetry. Bioassay results revealed that some of the title compounds showed potent insecticidal activities against oriental armyworm. Notably, compounds IIa, IIIa, IVa exhibited 100% activity at [Formula: see text], in particular, IIa showed a comparable control efficacy to that of the commercial product flubendiamide. The SAR of these N-cyano sulfiliminyl isomers can be summarized as follows (Sc, Ss) [Formula: see text] (Sc, Rs), while the N-trifluoroacetyl sulfiliminyl isomers is (Sc, Rs) [Formula: see text] (Sc, Ss). Comparative molecular field analysis indicated that an electropositive substituent, [Formula: see text] group in the benzene ring was very important for the improvement in biological activity. These results could hold promise for novel chiral sulfiliminyl RyR regulators.

Zhongguo Yaoshi (Beijing, China)

Analysis of SO₂ residues in Chinese prepared drug in pieces

Author: Bi, Wenyan

Objective: To analyze sulfur dioxide residues in com. Chinese prepared drug in pieces, in order to provide references for further development and improvement of circulation management specification of Chinese prepared drug in pieces.Methods: According to the method of measuring sulfur dioxide residues of introduced in Chinese Pharmacopoeia (supplementary I, 2010 edition), 19 types of Chinese prepared drug in pieces (platycodon grandiflorum, north straight ladybell, Chinese angelica, polygala, fritillaria, cortex dictamni, chrysanthemum, honeysuckle, pinellia tuber, yam, radix asparagi, radix trichosanthis, rhizoma gastrodiae, two tooth achyranthes root, rhizoma bletillae, atractylodis, radix paeoniae alba, dangshen and radix Puerariae thomsonii) provided by our company in the local area and some other manufacturers of Chinese prepared drug in pieces during 2010-2013 were tested.Results: In the 19 types including 136 batches of Chinese prepared drug in pieces, sulfur dioxide was not detected in 12 batches, accounting for 8.8% of the total; sulfur dioxide content was below the limits of its corresponding standard in 30 batches, 22.1% of the total; sulfur dioxide content was beyond the current recommended limits in 94 batches, 69.1% of the total.The maximum residue was seen in flower, being 2651 mg·kg^-1.Conclusion: More than 91% of the 19 types of Chinese prepared drug in pieces such as Dangshen, chrysanthemum, honeysuckles in the market at present have sulfur dioxide residues at different degrees, among them, the residue content in the 7 types, i.e., dangshen, Chinese angelica, radix trichosanthis, rhizoma gastrodiae, north straight ladybell, chrysanthemum, honeysuckle, is too high, to which attention should be paid.

100 Deals associated with Shenzhen Neptunus Bioengineering Co., Ltd.

100 Translational Medicine associated with Shenzhen Neptunus Bioengineering Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 14 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant Human Interleukin-2(125Ser) (Haiwang intlong) ( IL-2R )	Rheumatoid Arthritis More	Approved
MaZiRenWan	Constipation More	Approved
Recombinant human interferon alpha-2b (Haiwang intlong) ( IFNAR )	Lymphoma More	Approved
Polydatin	Microvascular Disease More	Phase 2
HW-130	Advanced Malignant Solid Neoplasm More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis